Amylyx Pharmaceuticals, Inc. Operating Income Loss

Quick Answer

Amylyx Pharmaceuticals, Inc. reported Operating Income Loss of -$153.29 million for the year ending 2025.

  • Amylyx Pharmaceuticals, Inc. showed an increase of +51.3% in Operating Income Loss from 2024 to 2025.
  • This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s Operating Income Loss has declined by 85.4%.
  • Historical annual values: Fiscal year 2025: -$153.29 million | Fiscal year 2024: -$314.73 million | Fiscal year 2023: $38.80 million | Fiscal year 2022: -$201.34 million | Fiscal year 2021: -$82.69 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: